Literature DB >> 10649280

Locally recurrent rectal cancer: role of composite resection of extensive pelvic tumors with strategies for minimizing risk of recurrence.

W J Temple1, E B Saettler.   

Abstract

Locally recurrent cancer of the rectum has been under-recognized as a complication, although it affects up to 40% of patients treated with surgery alone. Even in the best centers, rates average 25%. While radiotherapy may reduce recurrence, it is now apparent that total mesorectal excision is the most effective modality, with rates as low as 5%. The dramatic decrease in local recurrence can also be linked to increased survival in prospective studies, an effect more significant than any adjuvant therapy. The options, however, for patients with locally recurrent cancer are limited. Fifteen percent of patients with this complication die without systemic spread. Salvage by surgery offers potential cure. Other than anastomotic recurrences that can be locally resected, the best approach for long-term survival is an extensive surgical procedure requiring en bloc removal of adjacent organs and pelvic structures-so-called composite resection. With careful selection, 30% 5-year survival can be achieved and palliation is considerable, with 50% long-term local control. Intraoperative radiotherapy and brachytherapy, and/or preoperative chemoradiation may provide better results in future. Newer techniques of coloanal anastomosis, improved urinary diversion, and myocutaneous flaps for perineal reconstruction radically reduce the morbidity of these procedures. The approach to recurrent rectal cancer requires a sophisticated multidisciplinary team to obtain optimum results. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10649280     DOI: 10.1002/(sici)1096-9098(200001)73:1<47::aid-jso12>3.0.co;2-m

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

Review 1.  Surgical palliation in advanced disease: recent developments.

Authors:  Geoffrey P Dunn
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

2.  Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer.

Authors:  D-S Sun; J-D Zhang; L Li; Y Dai; J-M Yu; Z-Y Shao
Journal:  Br J Radiol       Date:  2011-03-08       Impact factor: 3.039

3.  Laparoscopic versus open lateral pelvic lymph node dissection in locally advanced rectal cancer: multicentre retrospective cohort study.

Authors:  Han-Ki Lim; Minjung Kim; Ji Won Park; Seung-Bum Ryoo; Kyu Joo Park; Heung-Kwon Oh; Duck-Woo Kim; Sung-Bum Kang; Dong Woon Lee; Sung Chan Park; Jae Hwan Oh; Seung-Yong Jeong
Journal:  BJS Open       Date:  2022-05-02

4.  Management of locally advanced primary and recurrent rectal cancer.

Authors:  Johannes H W de Wilt; Maarten Vermaas; Floris T J Ferenschild; Cornelis Verhoef
Journal:  Clin Colon Rectal Surg       Date:  2007-08

5.  Study of circumferential resection margin in patients with middle and lower rectal carcinoma.

Authors:  Ze-Yu Wu; Jin Wan; Jing-Hua Li; Gang Zhao; Lin Peng; Yuan Yao; Jia-Lin Du; Quan-Fang Liu; Zhi-Du Wang; Zhi-Ming Huang; Hua-Huan Lin
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

6.  Risk factors for local recurrence of middle and lower rectal carcinoma after curative resection.

Authors:  Ze-Yu Wu; Jin Wan; Gang Zhao; Lin Peng; Jia-Lin Du; Yuan Yao; Quan-Fang Liu; Hua-Huan Lin
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

7.  Preliminary results of phase I trial of oral uracil/tegafur (UFT), leucovorin plus irinotecan and radiation therapy for patients with locally recurrent rectal cancer.

Authors:  Masayoshi Yasui; Masataka Ikeda; Mitsugu Sekimoto; Hirofumi Yamamoto; Ichiro Takemasa; Takafumi Ueda; Junzo Shimizu; Mutsumi Fukunaga; Osamu Suzuki; Takehiro Inoue; Morito Monden
Journal:  World J Surg Oncol       Date:  2006-11-22       Impact factor: 2.754

8.  The efficacy and dosimetry analysis of CT-guided 125I seed implantation assisted with 3D-printing non-co-planar template in locally recurrent rectal cancer.

Authors:  Lu Wang; Hao Wang; Yuliang Jiang; Zhe Ji; Fuxin Guo; Ping Jiang; Xuemin Li; Yi Chen; Haitao Sun; Jinghong Fan; Weiyan Li; Xu Li; Junjie Wang
Journal:  Radiat Oncol       Date:  2020-07-25       Impact factor: 3.481

9.  Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer.

Authors:  Raphaëla C Dresen; Marleen J Gosens; Hendrik Martijn; Grard A Nieuwenhuijzen; Geert-Jan Creemers; Alette W Daniels-Gooszen; Adriaan J van den Brule; Hetty A van den Berg; Harm J Rutten
Journal:  Ann Surg Oncol       Date:  2008-04-04       Impact factor: 5.344

10.  Critical evaluation of contemporary management in a new Pelvic Exenteration Unit: The first 25 consecutive cases.

Authors:  Min Hoe Chew; Yu-Ting Yeh; Ee-Lin Toh; Stephen Aditya Sumarli; Ghee Kheng Chew; Lui Shiong Lee; Mann Hong Tan; Tiffany Priyanthi Hennedige; Shin Yi Ng; Say Kiat Lee; Tze Tec Chong; Hairil Rizal Abdullah; Terence Lin Hon Goh; Mohamed Zulfikar Rasheed; Kok Chai Tan; Choong Leong Tang
Journal:  World J Gastrointest Oncol       Date:  2017-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.